News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

John A. Moran Eye Center’s Voyant Biotherapeutics, LLC Enters Into Exclusive R&D Collaboration Agreement With Allergan Inc. (AGN)


2/21/2014 9:02:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY--(BUSINESS WIRE)--The John A. Moran Eye Center at the University of Utah today announced that Voyant Biotherapeutics, LLC, a company formed out of its Center for Translational Medicine (CTM), has signed an exclusive R&D Collaboration Agreement with Allergan, Inc. (NYSE: AGN), a multispecialty health care company headquartered in Irvine, Calif. The agreement provides for a combination of upfront, research and milestone payments. Under the agreement, the two companies will work together to identify disease-associated pathways and targets for the development of new therapeutic agents to treat ocular disease. A primary effort of this collaboration will be centered on new treatments for age-related macular degeneration (AMD), a leading cause of irreversible vision loss worldwide.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES